Value-Based Pricing

This post reports on an Issues Panel which was held at the Spanish Health Economics Association Annual Conference which took place in Granada, Spain 17-19 June 2015. The title of the panel was: Developing cost effectiveness for decision making: what can be learnt from “Value Based Pricing”?

A new OHE Consulting Report examines whether respondents completing abstract, hypothetical priority-setting exercises in stated preference studies agree with the policy implications of their choices.

The OHE presented the following posters at ISPOR 17th Annual European Congress in Amsterdam, The Netherlands.

ISPOR’s 17th Annual European Congress is scheduled for 8-12 November 2014 in Amsterdam. OHE’s Adrian Towse is current President of ISPOR and involved in several sessions. Important research on a range of topics will be...

OHE’s active involvement in a number of recent conferences and meetings has contributed to discussions on a range of important issue in health economics.

This research explores which approaches to pricing can produce the greatest efficiency and access to medicines within and across countries.
OHE collaborated on two articles published in the journal Health Economics recently.

OHE's contributions focused on approaches to implementing UK value-based assessment and the details of creating an EQ-5D-5L value set for England.
The Health Economists’ Study Group (HESG), based in the UK, was founded in 1972 to support and promote the work of health economists. Its members are from academic, commercial, and government settings.

Four types of economic incentives for drugs and diagnostics are essential to encouraging more rapid progress in personalised medicine.

Adrian Towse, OHE’s Director, and Lou Garrison, a professor at the University of Washington, summarise the critical economic issues in the development of evidence of value for drugs and diagnostics that are part of personalised medicine.

Performance-based risk sharing arrangements for prescription medicines and other treatments are attractive to payers because they promise to base what is paid for a treatment on whether/how well it actually works. Programmes typically include data collection and either implicitly or explicitly link pricing, reimbursement and/or revenue to what the data show.

OHE’s Dr Jorge Mestre-Ferrandiz is a visiting lecturer in the Department of Economics at City University London. As part of his 2013 activities, he recently gave a comprehensive lecture on the economics of the market for medicines in the UK. His presentation covers the key issues, from drug development through health technology assessment and market access.

Pages

Subscribe to RSS - Value-Based Pricing